Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Ceftazidime is a beta-lactam compound that exerts a time-dependent bactericidal effect. Numerous arguments are in favor of continuous administration of ceftazidime, both for reasons of clinical efficacy and to preserve bacteriological mutation. The investigators report a prospective, single-center, parallel-group, randomized, controlled trial comparing two modes of administration of ceftazidime, namely, continuous administration (loading dose of 20 mg/kg of body weight followed by 60 mg/kg/day) versus intermittent administration (20 mg/kg over 30 min every 8 h) in 34 patients with ventilator-associated pneumonia due to Gram-negative bacilli. The study was performed over 48 h with 13 and 18 assessments of serum ceftazidime in the continuous-infusion group (group A) and the intermittent-fusion group (group B), respectively. Bronchoalveolar lavage (BAL) was performed at steady state in both groups at 44 h to determine ceftazidime levels in the epithelial lining fluid. The investigators chose a predefined threshold of 20 mg/liter for serum concentrations of ceftazidime because of ecological conditions in our center.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CHU de Reims
• Treatments: Ceftazidime

Criteria

Inclusion Criteria

• Age >18 years;

• Patients hospitalized in the general intensive care unit of the University Hospital of Reims;

• Nosocomial pneumonia with Gram-negative.

Exclusion Criteria:

• Weight >110 kg;

• Pregnant or breastfeeding women;

• Known allergy to beta - lactam antibiotics;

• Renal impairment: clearance <60 calculated by the Cockcroft and Gault;

• Known history of pulmonary fibrosis;

• Patients included in another research protocol.